SUNNYVALE, Calif., March 15, 2022 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and therapeutics company, whose mission is to helping people access, understand and benefit from the human genome, announced today that it will present data related to its 23ME-00610 wholly owned immuno-oncology program at the upcoming 2022 annual meeting of the American Association for Cancer Research (AACR) to be held April 8-13, 2022 in New Orleans, Louisiana.
The summary details are as follows:
Abstract Title: 23ME-00610 is a first-in-class monoclonal antibody that targets the CD200R1 immune checkpoint to enhance T-cell mediated antitumor activity Presenting Author: Jill Fenaux Abstract Number: 602 / 12 Poster Session: Sunday, April 10, 2022, 1:30 – 5:00 p.m., New Orleans Convention Center, Exhibit Halls DH, Poster Section 38, Session PO.IM02.07 – Immune Checkpoints
Abstract Title: Discovery of CD200R1 as a Novel Immuno-Oncology Target Using Pleiotropic Signals from the 23andMe Genetic and Health Investigations Database Presenting Author: Xin Fang Abstract Number: 603 / 13 posting: Sunday, April 10, 2022, 1:30 PM – 5:00 PM, New Orleans Convention Center, Exhibit Halls DH, Poster Section 38, Session PO.IM02.07 – Immune Checkpoints
Electronic posters will be released at 12:00 p.m. CT on Friday, April 8 and will be available to registered attendees on the AACR 2022 website until Wednesday, July 13, 2022. Copies of the posters will also be available at https://investors. 23andme.com.
About 23andMe 23andMe, headquartered in Sunnyvale, Calif., is a leading consumer genetics and therapeutics company. Founded in 2006, the company’s mission is to help people access, understand and benefit from the human genome. 23andMe pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health risk reporting. The company has created the world’s largest crowdsourced platform for genetic research, with approximately 80% of its customers choosing to participate. The 23andMe research platform has generated over 180 publications on the genetic underpinnings of a wide range of diseases, conditions and traits. The platform also powers the 23andMe Therapeutics group, which currently pursues drug discovery programs rooted in human genetics in a range of disease areas, including oncology, respiratory and cardiovascular disease, in addition to other therapeutic areas. More information is available at www.23andMe.com.
Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limited to, statements regarding the future performance of 23andMe’s consumer genetics and therapeutics businesses and the growth and potential of its proprietary research platform. All statements, other than statements of historical facts, included or incorporated into this press release, including statements regarding strategy, financial condition, funding of continuing operations, cash reserves, projected costs, plans and 23andMe’s management objectives are forward-looking statements. . The words “believes”, “anticipates”, “estimates”, “plans”, “expects”, “intends”, “may”, “could”, “should”, “potential”, ” probable”, “projects”, “predicts”, “continues”, “will”, “plans” and “would” or, in each case, their negative or other variants or comparable terminology, are intended to identify forward-looking statements, although not all statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections regarding future events and various assumptions. 23andMe cannot guarantee that it will actually achieve any plans, intentions or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond 23andMe’s control) or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by such statements. prospective. The forward-looking statements contained herein are also subject to other risks and uncertainties that are described in 23andMe’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2021 filed with the Securities and Exchange Commission (” SEC”) on February 11. , 2022 and in subsequent filings by 23andMe with the SEC. The statements made herein are made as of the date of this press release and, except as required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments or otherwise. .